Clinical Trial Update: Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and amyloid imaging effects of subcutaneous bapineuzumab in mild-to-moderate Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Bapineuzumab (bapineuzumab)

Snippet

Sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED